María Díez Campelo-rekin lankidetzan egindako argitalpenak (12)

2022

  1. MDS-472 STAG2 and SRSF2 Mutations Might Define Prognosis of MDS Patients With Isolated Trisomy 8

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S316-S317

  2. Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes

    Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235

  3. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

    Haematologica, Vol. 106, Núm. 8, pp. 2215-2223

  2. Magnetic resonance myocardial feature tracking in transfusion-dependent myelodysplastic syndrome

    Journal of Cardiovascular Imaging, Vol. 29, Núm. 4, pp. 331-344

  3. Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 536-541

  4. Usefulness of myocardial T1 and T2 mapping with magnetic resonance in transfusion-dependent patients with low-risk myelodysplastic syndrome

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 630-633

2020

  1. The implication of ‘unknown significance’ variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene

    British Journal of Haematology

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  2. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

    British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

  3. Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

    International Journal of Laboratory Hematology, Vol. 41, Núm. 1, pp. 109-117

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359